Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Adaptive Study Design OK For Single-Arm Trials, FDA Says

Executive Summary

A newly finalized guidance document offers the US agency’s take on how and when clinical trials can be modified midstream. It includes some revisions from a draft version, including more attention paid the possibility of adaptive single-arm trials.


Related Content

Single-Arm Studies Can Have Adaptive Designs, Industry Tells FDA
Modifying Clinical Studies Midstream Can Be Done, With Caution, FDA Says





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst